Strides Pharma receives USFDA nod for Ibuprofen OTC oral suspension
Strides Pharma receives USFDA nod for Ibuprofen OTC oral suspension

Strides Pharma receives USFDA nod for Ibuprofen OTC oral suspension

Shreya Chaware Article rating: 5.0

On Wednesday, Strides Pharma informed that its wholly-owned subsidiary, Strides Pharma Global Pte Ltd (Singapore) has received approval for Ibuprofen oral suspension USP, 100 mg/5 ml (OTC) from United States Food & Drug Administration (USFDA).  

NSE semi-annual review: Tata Consumer Products replaces GAIL in Nifty 50; 24 stocks get replaced in Nifty 500
NSE semi-annual review: Tata Consumer Products replaces GAIL in Nifty 50; 24 stocks get replaced in Nifty 500

NSE semi-annual review: Tata Consumer Products replaces GAIL in Nifty 50; 24 stocks get replaced in Nifty 500

Karan Dsij Article rating: 5.0

In a semi-annual review, Index Maintenance Sub-Committee (Equity) has decided to make some replacement among stocks in various indices as part of its periodic review. While there was only one major change in the benchmark Nifty 50, it has replaced seven stocks in Nifty Next 50 index. These changes shall become effective from March 31, 2021.

Nifty forms inside bar pattern; 14,600 becomes crucial support level
Nifty forms inside bar pattern; 14,600 becomes crucial support level

Nifty forms inside bar pattern; 14,600 becomes crucial support level

Karan Dsij Article rating: 5.0

On the upside, for the bulls to regain their strength, it’s important for Nifty to sustain above the 21-EMA. As long as the index does not close above its 21-EMA, it would be a sell-on-rise market.

Self-interviewing before investing
Self-interviewing before investing

Self-interviewing before investing

Henil Shah Article rating: 3.8

Self-interviewing before investing would help you to avoid a lot of losses and unnecessary risks. Read onto find out more.

RSS
First18291830183118321834183618371838Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR